Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker ...

Akeso (AKESF) announced that its “globally first-in-class PD-1/VEGF bispecific antibody,” ivonescimab, has received approval from the National ...